Skip to content

Xencor XNCR Restricted Cash

Restricted Cash at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$816K0.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$25M0.0%
Absci Corporation logo
Absci CorporationABSI
$1.06M-93.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$147K+137%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$316K-0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's restricted cash?
Xencor (XNCR) reported restricted cash of $191K in Q1 2026.
How has Xencor's restricted cash changed year-over-year?
Xencor's restricted cash decreased by 32.7% year-over-year, from $284K to $191K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.